Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

This study tests DuoCAR20.19.22-D95, an experimental CAR-T cell therapy that targets three proteins (CD20, CD19, and CD22) found on certain B-cell blood cancers. CAR-T therapy involves modifying a patient's own immune cells in a lab to attack cancer cells. This trial is for patients whose B-cell cancer has returned or stopped responding to previous treatments. **You may be eligible if:** - You are an adult with a B-cell blood cancer (such as B-cell lymphoma or leukemia) that has relapsed or not responded to prior therapies - Your cancer has been confirmed by biopsy - You have had at least one prior treatment that did not work - You are in good enough health to tolerate the therapy - Women of childbearing potential must have a negative pregnancy test **You may NOT be eligible if:** - You are pregnant - You have active, uncontrolled infection - You have serious organ dysfunction (heart, liver, kidneys) - You have not had at least one prior line of treatment - You have a condition that makes CAR-T therapy unsafe Talk to your doctor to see if this trial is right for you.